Your browser doesn't support javascript.
loading
Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer.
Kwan, Edmond M; Fettke, Heidi; Crumbaker, Megan; Docanto, Maria M; To, Sarah Q; Bukczynska, Patricia; Mant, Andrew; Ng, Nicole; Foroughi, Siavash; Graham, Lisa-Jane K; Haynes, Anne-Maree; Azer, Sarah; Lim, Lisi Elizabeth; Segelov, Eva; Mahon, Kate; Davis, Ian D; Parente, Phillip; Pezaro, Carmel; Todenhöfer, Tilman; Sathianathen, Niranjan; Hauser, Christine; Horvath, Lisa G; Joshua, Anthony M; Azad, Arun A.
Afiliação
  • Kwan EM; Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.
  • Fettke H; Department of Medical Oncology, Monash Health, Melbourne, Australia.
  • Crumbaker M; Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.
  • Docanto MM; Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, New South Wales, Australia.
  • To SQ; Garvan Institute of Medical Research, New South Wales, Australia.
  • Bukczynska P; University of Sydney, New South Wales, Australia.
  • Mant A; Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.
  • Ng N; Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.
  • Foroughi S; Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Graham LK; Department of Medical Oncology, Eastern Health, Melbourne, Australia.
  • Haynes AM; Eastern Health Clinical School, Monash University, Melbourne, Australia.
  • Azer S; Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Lim LE; Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
  • Segelov E; Department of Medical Biology, The University of Melbourne, Melbourne, Australia.
  • Mahon K; Medical Oncology, Chris O'Brien Lifehouse, New South Wales, Australia.
  • Davis ID; Garvan Institute of Medical Research, New South Wales, Australia.
  • Parente P; Department of Urology, Monash Health, Melbourne, Australia.
  • Pezaro C; Department of Medical Oncology, Monash Health, Melbourne, Australia.
  • Todenhöfer T; Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia.
  • Sathianathen N; Department of Medical Oncology, Monash Health, Melbourne, Australia.
  • Hauser C; Garvan Institute of Medical Research, New South Wales, Australia.
  • Horvath LG; University of Sydney, New South Wales, Australia.
  • Joshua AM; Medical Oncology, Chris O'Brien Lifehouse, New South Wales, Australia.
  • Azad AA; Department of Medical Oncology, Eastern Health, Melbourne, Australia.
Transl Androl Urol ; 10(4): 1688-1699, 2021 Apr.
Article em En | MEDLINE | ID: mdl-33968657
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Transl Androl Urol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Austrália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Transl Androl Urol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Austrália